Equity markets notched their best performance on record in November as investors cheered three, separate, COVID-19 vaccines which posted pleasing results in late-stage trials. Market participants were quick to price in a sharper economic recovery, with monetary and fiscal policy remaining ultra-easy and the vaccine providing hope for a quicker return to normality in 2021. There was also further clarity for the market as Joe Biden’s election to the White House, combined with a split Congress, provided another positive catalyst for risk assets. The risk-on trade was fuelled by Joe Biden’s fiscal agenda and softer stance on trade, combined with the inability for Democrats to pass tax rises through Congress. Safe havens such as gold and US treasuries sold off whilst emerging markets tracked the positive sentiment seen across developed markets.

Although medium term expectations markedly improved, in the short-term the health crisis has worsened, COVID-19 restrictions in the West have tightened and economic momentum has slowed. Concerns remain over how economies were managing to deal with the pandemic as cases across the US and Europe continued to climb, resulting in further, stricter, lockdowns. Cases within the US hit 17 million by mid-December with deaths now well over 300,000. Similarly, within Europe, France implemented a new nationwide curfew as they struggled to quell a rise in cases. Germany also instituted a new nationwide lockdown. That said, investor concerns have been shrugged off throughout December as the positive vaccine news provided a light at the end of the tunnel whilst the prospect of further fiscal policy firmed, and central banks maintained their ‘lower-for-longer’ rhetoric.

Read the whole note here






Disclaimer: The value of investments and any income from them can go down as well as up and investors may not receive back their original investment amount. This communication is for information purposes only. It is not intended as a personal recommendation of particular financial instruments or strategies and it does not provide individually tailored investment advice. This document provides the views of the London & Capital Investment Team examining the fundamental background, economic outlook and possible effect on asset markets. This document is not an invitation to subscribe and is by way of information only. Nothing contained herein constitutes investment, legal, tax or other advice nor is it to be solely relied on in making an investment or other decision. If you are considering investing, you should consult your London & Capital adviser. The views expressed herein are those at the time of publication and are subject to change. Correct at time of going to press.
London and Capital Asset Management Limited is authorised and regulated by the financial conduct authority, 12 Endeavour square, London, E20 1JN. Firm reference number 143286. Registered in England and wales, company number 02112588. © London and Capital Asset Management Limited. All rights reserved. London and Capital Wealth Advisers Limited is authorised and regulated by the UK Financial Conduct Authority (firm reference number 120776) and by the U.S. Securities and Exchange Commission of 100 F street, NE Washington, DC 20549, with sec firm reference number 801-63787. Registered in England and Wales, company number 02080604. © London and Capital Wealth Advisers Limited. All rights reserved.